RNS | eCorporate 18 November 2020
ImmuPharma PLC
("ImmuPharma" or the "Company")
Total Share Capital Notification - Replacement
The following replaces the 'Total Share Capital Notification' announcement released on 30 September 2020 at 7.01am (BST) under RNS No 5041A.
In Section 2 below the reference to "Share Options in whole or part" should have stated 25,640,254 not 15,703,942.
The full amended text is shown below.
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that in accordance with its obligations to the Company's Euronext listing and following an application of Article 15 of the Belgian Law of 2 May 2007, the total number of shares with voting rights and the total number of voting rights are set out below:
|
Situation as at 16 June 2020 |
|
|
|
1. Information to be provided for on the basis of Article 15, §1, al. 1
|
|
|
|
Total of share capital (nominal value) |
: |
|
|
|
|
|
|
Total number of shares with existing voting rights (= denominator) - one vote per share |
: |
246,285,805 |
|
|
|
|
|
2. Additional information to be provided on the basis of Article 15, §1, al. 2
In respect to the announcement on 11 June 2020: "Investment from two specialist US healthcare investors" |
|
|
|
|
|
|
|
Convertible Securities (in whole or in part) into ordinary shares currently outstanding. The total conversion would result in an equal number of voting rights |
: |
10,734,166 |
|
|
|
|
|
Share options (in whole or in part) The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights.
|
: |
25,640,254 |
|
In respect to the announcements on 30 March 2020: "Subscription to raise |
|
|
|
|
|
|
|
Warrants over ordinary shares (in whole or in part) The exercise of the warrants would result in the creation of an equal number of ordinary shares and voting rights |
: |
3,343,045 |
|
|
|
|
|
Other outstanding rights to subscribe ordinary shares as detailed in the Annual Report 2019 (Report and consolidated financial Statements for the year ended 31 December 2019) |
|
|
|
|
|
|
|
Share options (in whole or in part) The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights |
: |
16,368,850 |
|
|
|
|
This situation (the denominator) serves as a basis for the notification of major holdings by shareholders.
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.